Seoul St. Mary's Hospital
cmc.or.krTotal trials
74
Active
6
Phase 3
3
Total enrollment
27,282
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Enavogliflozin 0.3mg | — | — | — | — | — | 1 | |
| Baracle Tab.® | — | — | — | — | — | 1 | |
| LuminoMark inj. 0.2mL | — | — | — | — | — | 1 |
Next readouts
- 2026-12-31
- 2027-04-29
- 2028-12-31
Top conditions
- Lung Cancer3
- Chronic Myeloid Leukemia3
- Cholecystitis, Acute3
- Oxidative Stress2
- Colorectal Cancer2
- Myelodysplastic Syndrome2
- Thyroid Cancer2
- Chronic Myelocytic Leukemia2
Frequently asked questions about Seoul St. Mary's Hospital
- How many clinical trials does Seoul St. Mary's Hospital have on ClinicalTrials.gov?
- Seoul St. Mary's Hospital is listed as the lead sponsor on 74 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Seoul St. Mary's Hospital's trials are in Phase 3?
- 3 of Seoul St. Mary's Hospital's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Seoul St. Mary's Hospital focus on?
- Seoul St. Mary's Hospital's most-studied conditions on ClinicalTrials.gov are Lung Cancer, Chronic Myeloid Leukemia, Cholecystitis, Acute, Oxidative Stress, Colorectal Cancer.
- When are Seoul St. Mary's Hospital's next clinical trial readouts?
- Seoul St. Mary's Hospital has 3 upcoming primary-completion readouts tracked here; the soonest is “Confirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorectal Cancer Surgery.”, expected around 2026-12-31.